Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: Two case reports and review of the literature

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1001-1009

  Lamoth, Frédéric ^a,b   Pascual, Manuel ^b   Erard, Véronique ^a   Venetz, Jean Pierre ^b   Nseir, Ghaleb ^b   Meylan, Pascal ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CIDOFOVIR; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BLOOD TOXICITY; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; POLYOMA VIRUS; POLYOMAVIRUS ASSOCIATED NEPHROPATHY; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; BK VIRUS; CYTOSINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 58149508325     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26:671-673.
2. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006; 69:655-662.
3. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347:488-496.
4. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277-1286.
5. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13:2145-2151.
6. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68:1834-1839.
7. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997; 41:587-593.
8. Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005; 79:116-118.
9. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8:95-101.
10. Portolani M, Pietrosemoli P, Cermelli C, et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988; 9:205-218.
11. Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Cbemother 2006; 50:1564-1566.
12. Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother 2008; 52:1519-1521.
13. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007; 5:105-115.
14. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-596.
15. Kendle JB, Fan-Havard P. Cidofovir in the treatment of cytomegaloviral disease. Ann Pharmacother 1998; 32:1181-1192.
16. Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17:148-149.
17. Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-incluced end-stage renal failure. Clin Infect Dis 1999; 29:948-949.
18. Vats A, Shapiro R, Singh RP, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75:105-112.
19. Drachenberg RC, Drachenberg CB, Papadinuitriou JC, et al. Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology. Am J Transplant 2001; 1:373-381.
20. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003; 3:186-191.
21. Lim WH, Mathew TH, Cooper JE, Bowden S, Russ GR. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology 2003; 8:318-323.
22. Limaye AP, Smith KD, Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5:614-620.
23. Araya CE, Lew JF, Fennell RS, III, Neiberger RE, Dharnidharka VR. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant 2006; 10:32-37.
24. Biorang O, Tveitan H, Midtvedt K, Broch LU, Scott H, Andresen PA. Treatment of polyomavirus infection with cidofovir in a renal-transplant recipient. Nephrol Dial Transplant 2002; 17:2023-2025.
25. Ginevri F, Pastorino N, de Santis R, et al. Retransplantation after kidney graft loss due to polyoma BK virus nephropatby: successful outcome without original allograft nephrectomy. Am J Kidney Dis 2003; 42:821-825.
26. Gupta G, Shapiro R, Thai N, Randhawa PS, Vats A. Low incidence of BK virus nephropathy after simultaneous kidney pancreas transplantation. Transplantation 2006; 82:382-388.
27. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004; 8:485-492.
28. Keller LS, Peh CA, Nolan J, Bannister KM, Clarkson AR Faull RJ. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003; 18:1013-1014.
29. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005; 5:1997-2004
30. Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4:2132-2134.
31. Puliyanda DP, Toyoda M, Traum AZ, et al. Outcome of management strategies for BK virus replication in pediatric renal transplant recipients. Pediatr Transplant 2008; 12:180-186.
32. Tong CY, Hilton R, MacMahon EM, et al. Monitoring the progress of BK virus associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 2004; 19:2598-2605.
33. Comoli P, Azzi A, Maccario R, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78:1229-1232.
34. Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727-2735.
35. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84:83-88.
36. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10:920-922.
37. Ott U, Steiner T, Busch M, Gerth J, Wolf G. A singte-centre experience with BK virus nephropathy. Clin Nephrol 2008; 69:244-250.
38. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008; 8:1413-1422.
39. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995; 39:1247-1252.
40. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003; 59:163-171.
41. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl- [2-(14)C]cidofovir in MRC-S human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003; 63:678-681.
42. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20:962-969.
43. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81:704-710.
44. Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 2005; 5:2582-2585.
45. Lipshutz GS, Mahanty H, Feng S, et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years posttransplant. Am J Transplant 2005; 5:366-373.
46. Lopez V, Sola E, Gutierrez C, et al. Anterior uveitis associated with treatment with intravenous cidofovir in kidney transplant patients with BK virus nephropathy. Transplant Proc 2006; 38:2412-2413.